UBM's BioLIVE Event to Introduce Global Biopharma Country Ranking

Events firm UBM’s bioprocessing and manufacturing expo, bioLIVE, which will debut this October alongside CPhI Worldwide trade fair in Madrid, is introducing a biologics manufacturing and processing league table, which will rank the perception of the world’s largest biologics markets for ‘overall quality’, ‘growth potential’ [for exports and domestic market], ‘innovation’ and ‘ability to meet future capacity constraints’.

This follows the global small molecule country rankings launched by UBM last year.

“Biologics capacity is growing quickly and will increase by nearly 40% over the next four years. Asia and European countries are building more facilities, which is reducing the USA’s overall market share of capacity. What no one has yet evaluated is the relative perceived strengths of each region. The perception of each country will undoubtedly be a factor in realising its growth potential,” explained Mr. Rutger Oudejans, Brand Director at UBM for bioLIVE.

The study will evaluate the consequences for the supply chain, as with an increasing number of bio facilities globally, the perception of the ability to meet future demand could well be a decisive factor in major investment decisions. “What will also become clearer is which markets are seen to have the best potential growth both domestically and for exports,” UBM said.

“Last year’s small molecule ranking demonstrated that the traditional economies of the USA, Germany and Japan were still perceived as the strongest, but with the rapid emergence of newer bio regions – we could see countries like Korea, China and Singapore ranking much higher for large molecule manufacturing. Additionally, the research will also evaluate what the potentially geopolitical and supply chain risk is in newer regions, as well as the knowledge of bio professionals. Thus, we might see a picture emerging of certain countries being seen as exceptional for capacity and production, and others for knowledge and innovation,” UBM added in a press note.